Denosumab, a potential game-changer for Amgen Inc, is expected to be the most notable launch in the biotech industry in years. However, many on Wall Street expect the FDA’s approval decision to be delayed by about three months from the expected date of October 19 because the agency has a history of missing deadlines and may want more time to analyze the safety record of a new drug like denosumab.